Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

86
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
86

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic impact of interpretation criteria for [<sup>18</sup>F]PSMA-1007 PET/CT: Prospective comparison with CT and bone scan.

European journal of nuclear medicine and molecular imaging·2026
Same author

Characterization and first application of a new <sup>236</sup>Np spike for (A)MS measurements of <sup>237</sup>Np.

Talanta·2026
Same author

Tellurium-118 as a novel radionuclide for long-term positron emission tomography.

Scientific reports·2026
Same author

Breaking the Immiscibility Barrier: A Mechanochemical Approach to Enable the Direct Glycosylation of Native Sugars with Hydrophobic Aliphatic Alcohols.

Journal of the American Chemical Society·2026
Same author

Flavonoid Interactions with Renal Organic Anion Transporters OAT1 and OAT3: Structure-Activity Relationships and Clinical Implications.

International journal of molecular sciences·2026
Same author

Enhanced tumor retention of the novel LAT1-targeting PET probe [<sup>18</sup>F]FAMT-OMe: A comparative study with [<sup>18</sup>F]FAMT in glioma mouse models.

Nuclear medicine and biology·2026

Related Experiment Video

Updated: Jun 6, 2025

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.6K

Development of LAT1-Selective Nuclear Medicine Therapeutics Using Astatine-211.

Kazuko Kaneda-Nakashima1,2, Yoshifumi Shirakami2, Kentaro Hisada1

  • 1Radiation Biological Chemistry, MS-CORE, FRC, Graduate School of Science, Osaka University, 1-1 Machikaneyama-cho, Toyonaka, Osaka 560-0043, Japan.

International Journal of Molecular Sciences
|November 27, 2024
PubMed
Summary

Researchers developed a novel nuclear medicine therapeutic targeting the L-type amino acid transporter 1 (LAT1). This new compound, utilizing astatine-211, shows enhanced retention and superior therapeutic effects for LAT1-targeting treatments.

Keywords:
LAT1amino acidastatine-211cancer therapynuclear medicine

More Related Videos

Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method
09:08

Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method

Published on: December 20, 2024

1.3K
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

8.7K

Related Experiment Videos

Last Updated: Jun 6, 2025

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

7.6K
Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method
09:08

Enhancing Efficiency and Radiolabeling Yields of Carbon-11 Radioligands for Clinical Research Using the Loop Method

Published on: December 20, 2024

1.3K
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

8.7K

Area of Science:

  • Nuclear medicine
  • Radiopharmaceutical chemistry
  • Molecular imaging and therapy

Background:

  • L-type amino acid transporter 1 (LAT1) is a key target for cancer therapy.
  • Previous development of astatine-211 (211At)-based therapeutics targeting LAT1 showed promise.
  • Optimization of radiolabeling and compound structure is crucial for therapeutic efficacy.

Purpose of the Study:

  • To develop an improved nuclear medicine therapeutic agent targeting LAT1.
  • To enhance the retention and therapeutic effect of 211At-labeled LAT1-targeting compounds.
  • To identify optimal structural modifications for improved radiopharmaceutical properties.

Main Methods:

  • Synthesis and evaluation of novel 211At-labeled compounds based on 3-Astatomethyl-L-tyrosine.
  • Investigation of structure-retention relationships by modifying the phenol group.
  • Comparative analysis of uptake kinetics and biodistribution of different isomers and analogs.
  • Assessment of therapeutic efficacy in preclinical models.

Main Results:

  • Modification of the phenol hydroxyl group to a methyl group significantly increased compound retention.
  • The L-isomer demonstrated superior uptake compared to the D-isomer.
  • Replacing the methyl group with ethyl or propyl groups did not improve retention and led to increased non-specific accumulation.
  • A simplified structure, 211At-AAMT-O-Me-L, exhibited faster uptake and favorable properties.

Conclusions:

  • Structural modifications, specifically methylation of the phenol group, are critical for enhancing the retention of 211At-labeled LAT1-targeting radiopharmaceuticals.
  • The developed compound, 211At-AAMT-O-Me-L, offers advantages in terms of ease of labeling, high specific radioactivity, stability, and potent therapeutic effects.
  • This optimized radiopharmaceutical represents a promising advancement in targeted nuclear medicine therapy for LAT1-expressing conditions.